Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3202626 in mild Alzheimer's disease
NCT02791191Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of LY3202626 in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Jun 2016; status: terminated.
02
Drugs
LY3202626
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02791191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791191.